急性ST段抬高型心肌梗死患者血清视黄醇结合蛋白4、超氧化物歧化酶和超敏C反应蛋白的表达及临床意义
治疗前各组血清RBP4、SOD和hs-CRP无显著差异;在多支血管病变组中,SYNTAX评分与RBP4和hs-CRP显著相关,与SOD无相关;高危评分与RBP4和hs-CRP水平密切相关。不同他汀治疗的患者预后无显著差异。结论认为联合检测RBP4、SOD和hs-CRP可作为预测STEMI风险的较好指标。
要点
- 多支血管病变STEMI患者中,SYNTAX评分与血清RBP4和hs-CRP显著相关(双支病变r值分别为0.616和0.489,三支病变r值分别为0.423和0.357,均P<0.05)。
- 多支血管病变组中SYNTAX评分与SOD无相关性(双支r=0.108,三支r=0.055,均P>0.05)。
- STEMI高危评分与RBP4和hs-CRP水平密切相关(r值分别为0.581和0.623,均P<0.01)。
- 治疗前不同血管病变组间血清RBP4、SOD和hs-CRP无显著差异。
- 阿托伐他汀钙组与瑞舒伐他汀钙组高危患者分别为8例和7例,死亡患者分别为2例和3例,预后无显著差异(均P>0.05)。
适用人群与场景
- (本栏提炼含原文里核对不到的数值,已删除,请以原文为准)
诊断标准与关键阈值
- 原文未提及
处置流程与药物剂量
- 在常规治疗基础上,给予阿托伐他汀钙或瑞舒伐他汀钙治疗(原文未提及具体剂量、途径、频次或疗程)。
- 根据冠状动脉造影结果分为单支、双支和三支病变组,并进行SYNTAX评分。
- 检测治疗前后血清RBP4、SOD和hs-CRP水平。
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 干预为常规治疗基础上阿托伐他汀钙或瑞舒伐他汀钙治疗,对照为不同他汀药物组间比较。
- 主要终点:治疗前不同血管病变组间血清RBP4、SOD和hs-CRP无显著差异。
- 多支血管病变组中SYNTAX评分与RBP4和hs-CRP显著相关(双支病变r值分别为0.616和0.489,三支病变r值分别为0.423和0.357,均P<0.05),与SOD无相关(r值分别为0.108和0.055,均P>0.05)。
- 高危评分与RBP4和hs-CRP水平密切相关(r值分别为0.581和0.623,均P<0.01)。
- 阿托伐他汀钙组和瑞舒伐他汀钙组高危患者分别为8例和7例,死亡患者分别为2例和3例,预后无显著差异(均P>0.05)。
证据类型、等级与局限
- 证据类型:单中心临床研究(原文未标注证据等级或推荐强度)。
对床旁实践的改变
- 原文结论认为联合检测血清RBP4、SOD和hs-CRP水平可作为预测STEMI风险的较好指标,值得临床应用;但研究为单中心小样本,相关分析不能等同于决策阈值,需前瞻性验证。
- 不同他汀(阿托伐他汀钙与瑞舒伐他汀钙)治疗组预后无显著差异,原文未提供剂量方案,不能据此改变他汀选择。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To analyze the expression and clinical significance of serum retinol binding protein 4 (RBP4), superoxide dismutase (SOD) and hypersensitive C-reactive protein (hs-CRP) in patients with acute ST-segment elevated myocardial infarction (STEMI).
METHODS: Seventy-eight patients with STEMI who underwent percutaneous coronary intervention (PCI) admitted to Nanxishan Hospital of Guangxi Zhuang Autonomous Region from January 2017 to March 2019 were enrolled. On the basis of the routine treatment, atorvastatin calcium or rosuvastatin calcium treatment was given. According to the results of coronary angiography, the patients were divided into three groups: single-vessel, double-vessel and three-vessel lesions, and the severity of coronary artery disease score (SYNTAX score) was performed. The serum RBP4, SOD and hs-CRP were measured and compared among different groups before and after treatment. The correlation between the three serum parameters of STEMI patients and the SYNTAX score, risk prediction (STEMI high-risk score) and prognosis were recorded and compared among different groups.
RESULTS: There was no significant difference in serum RBP4, SOD and hs-CRP among different groups before treatment. In multivessel (double-vessel and three-vessel) vascular disease group, SYNTAX score was significantly correlated with RBP4 and hs-CRP (double-vessel lesions: r values were 0.616 and 0.489 respectively, three-vessel lesions: r values were 0.423 and 0.357 respectively, all P < 0.05), but had no correlation with SOD (r values were 0.108 and 0.055 respectively, both P > 0.05), and high-risk score was closely correlated with RBP4 and hs-CRP levels (r values were 0.581 and 0.623 respectively, both P < 0.01). There was no significant difference in the prognosis of patients treated with different statins. There were 8 and 7 high-risk patients in the atorvastatin calcium group and rosuvastatin calcium group, respectively, and 2 and 3 dead patients respectively (both P > 0.05).
CONCLUSIONS: Combined detection of serum RBP4, SOD and hs-CRP levels can be used as better indicators to predict the risk of STEMI, which is worthy of clinical application.
参考来源
- Li J, Huang X, Jiang Y, et al. [Expression and clinical significance of serum retinol binding protein 4, superoxide dismutase and hypersensitive C-reactive protein in patients with acute ST-segment elevated myocardial infarction]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2020. PMID: 33198863. doi:10.3760/cma.j.cn121430-20200113-00132
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。